Rovast 20 MG


Rovast 20 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)






Rosuvastatin is indicated for

  • heterozygous hypercholesterolemia (familial and non-familial)
  • homozygous hypercholesterolemia (familial)
  • mixed dyslipidemia (Fredrickson type IIa and IIb)
  • cardiovascular disease Primary prevention



Rosuvastatin is a selective and competitive inhibitor of HMGCoA reductase. HMGCoA reductase is the limit for the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonate (a cholesterol precursor). Speed ​​enzyme. Rosuvastatin produces its lipid modification effect in two ways. First, it increases the number of liver low-density lipoprotein receptors on the cell surface to enhance the absorption and catabolism of low-density lipoprotein. Secondly, Rosuvastatin inhibits liver VLDL synthesis and reduces the total number of VLDL and LDL particles.


Dosage & Administration

Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg

HoFH: Starting dose 20 mg/day.

Pediatric patients with HeFH: 5-10 mg/day for patients 8 to less than 10 years age, and 5-20 mg/day for patients 10 to 17 years of age.

Pediatric patients with HoFH: 20 mg/day for patients 7 to 17 years of age.



Remarkable drug interactions of Rosuvastatin are-

  • Cyclosporine: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be limited to 5 mg once daily.
  • Gemfibrosil: Combination should be avoided. If used together, Rosuvastatin dose should be limited to 10 mg once daily.
  • Lopinavir/Ritonavir or atazanavir/ritonavir: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be to 10 mg once daily.
  • Coumarin anticoagulants: Combination prolongs international normalized ratio (INR). Stable INR should be achieved prior to starting Rosuvastatin. INR should be monitored frequently until stable upon initiation or alteration of Rosuvastatin therapy.
  • Concomitant lipid-lowering therapies: Use with fibrates and niacin products may increase the risk of skeletal muscle effects.



Rosuvastatin is contraindicated if-

  • Known hypersensitivity to product components
  • Liver disease, which may include unexplained persistent elevations in hepatic transaminase levels
  • Pregnant women and women who may become pregnant
  • Nursing mothers


Side Effects

In general, rosuvastatin is well tolerated. The most common adverse events thought to be related to rosuvastatin are headache, myalgia, constipation, weakness, abdominal pain, and nausea.


Pregnancy & Lactation

The safety of pregnant women has not been determined. It is unknown whether rosuvastatin is excreted in human milk.


Precautions & Warnings

Effects on skeletal muscle (eg, myopathy and rhabdomyolysis): risk varies with 40 mg dose, advanced age (> 65 years), hypothyroidism, renal impairment, and interaction with cyclosporine, lopinavir / ritone Weir, atazanavir / ritonavir, or some other Lipid-lowering drugs are used in combination. Patients should be advised to report unexplained muscle pain, tenderness, or weakness early. If signs or symptoms appear, rosuvastatin can be stopped.

Abnormal liver enzymes and monitoring: Continuous elevation of liver transaminases may occur.

Liver enzymes should be monitored before and during treatment.


Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs, Statins


Storage Conditions

Keep below 30oC temperature, protected from light & moisture. Keep out of the reach of children.


Pharmaceutical Name

Healthcare Pharmaceuticals Ltd.